Literature DB >> 11467466

Components of clinical trials for vasovagal syncope.

R Sheldon1, S Rose.   

Abstract

The time is ripe for adequately powered, randomized, placebo-controlled clinical trials in vasovagal syncope. Vasovagal syncope is a common syndrome, the symptoms of which can be troublesomely frequent. It is usually diagnosed by tilt-table testing, although this has persistent problems with both sensitivity and specificity. Patients with syncope and positive tilt tests have been the subjects of numerous studies of natural history, risk stratification, and treatment. This paper discusses studies of treatments for vasovagal syncope in the context of a classification of the levels of evidence that can be gleaned from clinical studies. The reasons for placebo-controlled trials are reviewed, as is the evidence for various methods of risk stratification. Data for power calculations are presented for the primary outcome, the time to the first syncope recurrence. Strengths and weakness of the four main types of outcomes for clinical trials are compared.

Entities:  

Mesh:

Year:  2001        PMID: 11467466     DOI: 10.1053/eupc.2001.0168

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  6 in total

1.  [From loss of consciousness to syncope].

Authors:  H-H Ebert; C Walter; H Volkmann
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2011-06

Review 2.  Has cardiac pacing a role in vasovagal syncope?

Authors:  Richard Sutton
Journal:  J Interv Card Electrophysiol       Date:  2003-10       Impact factor: 1.900

3.  Implantable Loop Recorder: Diagnostic Yield And Possible Therapeutic Effect In Patients With Neurally Mediated Reflex Syncope.

Authors:  M Unterhuber; W Rauhe; P Sgobino; F Pescoller; M Manfrin; M Tomaino
Journal:  J Atr Fibrillation       Date:  2016-08-31

Review 4.  Nonpharmacological treatment of reflex syncope.

Authors:  Wouter Wieling; Nancy Colman; C T Paul Krediet; Roy Freeman
Journal:  Clin Auton Res       Date:  2004-10       Impact factor: 4.435

5.  Clinical efficacy of beta1 selective adrenergic blockers in the treatment of neurocardiogenic syncope - a meta-analysis.

Authors:  Srikanth Vallurupalli; Smita Das
Journal:  Clin Pharmacol       Date:  2010-09-15

6.  Positive result in the early passive phase of the tilt-table test: a predictor of neurocardiogenic syncope in young men.

Authors:  Jae-Sun Uhm; Ho-Joong Youn; Woo-Baek Chung; Yun-Seok Choi; Chul-Soo Park; Yong-Seog Oh; Wook-Sung Chung; Kyung-Il Park; Tae-Suk Kim
Journal:  Korean J Intern Med       Date:  2012-02-28       Impact factor: 2.884

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.